AL Hilal Pharmacy Pharmaceutical Import Profile — Yemen (DGFT 2022–2026)

Name: AL Hilal Pharmacy Pharmaceutical Import Records from India — 5 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AL Hilal Pharmacy — Pharmaceutical Importer Profile (2026) | 5 Products, $1.4M Trade | TransData Nexus

AL Hilal Pharmacy

Pharmaceutical Importer · Yemen · Gastrointestinal Focus · $1.4M Total Trade · DGFT Verified

AL Hilal Pharmacy is a pharmaceutical importer based in Yemen with a total trade value of $1.4M across 5 products in 3 therapeutic categories. Based on 29 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. AL Hilal Pharmacy sources from 3 verified Indian suppliers, with Innova Captab Limited accounting for 97.7% of imports.

AL Hilal Pharmacy — Import Portfolio & Supplier Network

AL Hilal Pharmacy import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AL Hilal Pharmacy?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Innova Captab Limited	$2.6M	169	97.7%
Zuche Pharmaceuticals Privatelimited	$49.0K	4	1.8%
Excel Global Health	$12.5K	2	0.5%

What Formulations Does AL Hilal Pharmacy Import?

Formulation	Value	Ships
Serravent-d (serratiopeptidase &	$205.1K	6
Pantovent-d (pantoprazole &	$113.9K	3
Ventocortil-20 (prednisolone tablets	$110.8K	3
Pantovent INJ (pantoprazole for	$107.8K	3
Clarilite antimarks cream (hydr.,tert.	$107.3K	3
Dapalift-10 (dapagliflozin tablets 10MG)	$104.3K	3
Galvent-m 500 (vildagliptin &	$104.3K	3
Candivent-vt (clind,clotr.,metro &	$104.0K	3
Cortidron-100 (hydro sodium succinate	$103.8K	3
Duopress-fm (flupentixol & melitracen	$103.4K	3
Lipivent-20 (atorvastatin tablets USP	$103.4K	3
Primovent-n (norethisterone tablets	$103.4K	3
Mylabion (methylcobalamin with alpha	$103.2K	3
Rtrit-INJ 60 MG (artesunate for	$102.4K	3
Colivent drops (dill oil, fennel oil	$102.0K	3

AL Hilal Pharmacy imports 109 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pantoprazole	Gastrointestinal	$750.0K	15	0.1%	16
2	Dapagliflozin	Advanced Diabetes Medications	$200.0K	4	0.4%	18
3	Vildagliptin	Advanced Diabetes Medications	$200.0K	4	2.0%	3
4	Domperidone	Gastrointestinal	$150.0K	3	0.5%	2
5	Prednisolone	Respiratory	$150.0K	3	0.2%	12

AL Hilal Pharmacy imports 5 pharmaceutical products across 3 categories into Yemen totaling $1.4M.

AL Hilal Pharmacy — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AL Hilal Pharmacy is a pharmaceutical importer and distributor based in Aden, Yemen. Established in 2007, the company has been instrumental in supplying a diverse range of pharmaceutical products to the Yemeni market. Operating as a key player in Yemen's pharmaceutical distribution network, AL Hilal Pharmacy imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. The company's mission is to provide high-quality medicines at accessible prices, ensuring availability across the country.

Over the years, AL Hilal Pharmacy has developed a robust portfolio, importing a total of 109 unique formulations across five product categories. The company's strategic focus on sourcing from India has enabled it to offer a wide array of pharmaceutical products, catering to various therapeutic needs within Yemen. This approach underscores AL Hilal Pharmacy's commitment to meeting the healthcare demands of the Yemeni population through reliable and diverse pharmaceutical imports.

2Distribution Network

While specific details about AL Hilal Pharmacy's warehouse locations and logistics capabilities are not publicly disclosed, the company is known to operate from Aden, Yemen. Given Aden's strategic position as a major port city, it is likely that AL Hilal Pharmacy utilizes this advantage to facilitate the importation and distribution of pharmaceutical products. The company's distribution network is presumed to cover major cities and regions within Yemen, ensuring that imported medicines reach a broad customer base. However, without explicit information on their logistics infrastructure, a comprehensive assessment of their geographic coverage and logistics capabilities remains speculative.

3Industry Role

AL Hilal Pharmacy plays a pivotal role in Yemen's pharmaceutical supply chain as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of essential medicines to the Yemeni market. This role is crucial in a country where access to a diverse range of pharmaceutical products is vital for public health. Through its import and distribution activities, AL Hilal Pharmacy contributes significantly to the healthcare infrastructure of Yemen, facilitating the availability of necessary medications across the nation.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AL Hilal Pharmacy

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AL Hilal Pharmacy's sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from a single supplier, INNOVA CAPTAB LIMITED. This supplier accounts for approximately 97.7% of the total import value, indicating a strong reliance on this partnership. Such a concentrated sourcing approach can offer benefits like streamlined procurement processes and potentially favorable pricing. However, it also introduces risks associated with supplier dependency, including potential disruptions in supply due to issues like production delays, quality concerns, or geopolitical factors affecting trade relations.

The stability of AL Hilal Pharmacy's relationship with INNOVA CAPTAB LIMITED is suggested by the consistent volume of imports over the years. Nonetheless, the lack of diversification in sourcing could pose challenges in maintaining a continuous and reliable supply chain. To mitigate these risks, it would be prudent for AL Hilal Pharmacy to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing potential vulnerabilities associated with over-reliance on a single supplier.

2Supply Chain Resilience

The resilience of AL Hilal Pharmacy's supply chain is closely tied to its sourcing strategy, which is predominantly concentrated on a single supplier, INNOVA CAPTAB LIMITED. This concentration can lead to vulnerabilities, as any disruptions affecting this supplier—such as production issues, quality control problems, or geopolitical tensions—could significantly impact AL Hilal Pharmacy's ability to meet market demand. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies further underscores the potential risks associated with this dependency.

Importing Pharmaceuticals into Yemen — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Yemen

1Regulatory Authority & Framework

In Yemen, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Public Health and Population. This ministry is responsible for establishing and enforcing regulations related to the importation, registration, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Customs Law No. 14 of 1990 and its subsequent amendments, which outline the procedures and requirements for importing goods into Yemen. Notably, Law No. 5 of 2020 amended the Customs Law to exempt certain pharmaceutical production inputs from customs duties, aiming to facilitate the availability of essential medicines in the country.

The marketing authorization pathway for Indian generics involves several steps. Initially, the pharmaceutical product must be registered with the Ministry of Public Health and Population, which includes submitting a Certificate of Pharmaceutical Products (COPP) issued by the competent authority in the country of origin, such as the U.S. FDA. This certificate verifies the authenticity and regulatory compliance of the product. The COPP must undergo legalization to be recognized by Yemeni authorities, a process that involves certification and embassy verification to confirm the document's authenticity.

2Import Licensing & GMP

To import pharmaceutical products into Yemen, companies must obtain an import license from the Ministry of Public Health and Population. This process requires registration as an importer with the Ministry of Industry and Trade and may involve additional licenses depending on the product category. Compliance with Good Manufacturing Practice (GMP) standards is mandatory, and imported products must be accompanied by certificates confirming adherence to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, wholesale distribution authorization is required to operate as a distributor within Yemen, ensuring that all imported pharmaceutical products are handled and distributed in accordance with national regulations.

AL Hilal Pharmacy — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AL Hilal Pharmacy's product strategy focuses on importing pharmaceutical formulations across five categories, with a significant emphasis on gastrointestinal medications (62.1%), advanced diabetes medications (27.6%), and respiratory treatments (10.3%). This strategic focus aligns with the prevalent health concerns in Yemen, where gastrointestinal disorders, diabetes, and respiratory diseases are common. By concentrating on these therapeutic areas, AL Hilal Pharmacy addresses critical healthcare needs, ensuring that essential medications are accessible to the Yemeni population.

The market demand driving these imports is influenced by factors such as the prevalence of specific diseases, demographic trends, and the availability of healthcare services. For instance, the high incidence of diabetes in Yemen necessitates a steady supply of advanced diabetes medications. Similarly, the prevalence of gastrointestinal and respiratory conditions underscores the need for effective treatments in these categories. AL Hilal Pharmacy's product strategy is thus a direct response to these market demands, aiming to improve health outcomes by providing targeted pharmaceutical solutions.

2Sourcing Profile

AL Hilal Pharmacy's sourcing strategy is predominantly focused on importing generic drugs, primarily from India.

TransData Nexus Research · DGFT trade data analysis

Frequently Asked Questions — AL Hilal Pharmacy

What products does AL Hilal Pharmacy import from India?

AL Hilal Pharmacy imports 5 pharmaceutical products across 3 categories. Top imports: Pantoprazole ($750.0K), Dapagliflozin ($200.0K), Vildagliptin ($200.0K), Domperidone ($150.0K), Prednisolone ($150.0K).

Who supplies pharmaceuticals to AL Hilal Pharmacy from India?

AL Hilal Pharmacy sources from 3 verified Indian suppliers. The primary supplier is Innova Captab Limited (97.7% of imports, $2.6M).

What is AL Hilal Pharmacy's total pharmaceutical import value?

AL Hilal Pharmacy's total pharmaceutical import value from India is $1.4M, based on 29 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AL Hilal Pharmacy focus on?

AL Hilal Pharmacy imports across 3 categories. The largest: Gastrointestinal (62.1%), Advanced Diabetes Medications (27.6%), Respiratory (10.3%).

Get Full AL Hilal Pharmacy Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.